{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.5","upperLimit":"33.7","value":"18.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Whether or not the patient survived progression-free for at least 6 months.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nTrebananib: Given IV","id":"OG000","title":"Treatment (Trebananib)"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"At 6 months","title":"Progression-free Survival > 6 Months","type":"PRIMARY","unitOfMeasure":"percentage of participants"}